Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical ...

Microbiotica’s MB097, an oral microbiome-based therapy, shows promise in boosting immunotherapy response in melanoma patients ...

Merck has launched construction of a $1 billion biologics facility in Wilmington, set to become the U.S. production hub for ...

The US FDA has cleared the investigational new drug (IND) application to begin clinical trials for BFB-101, a novel gene ...

Pfizer’s sasanlimab, combined with BCG therapy, significantly improved event-free survival in patients with BCG-naïve, ...

Enhertu (trastuzumab deruxtecan), in combination with pertuzumab, shows promise as a new first-line treatment for ...

The Phase 3 ASCENT-04 clinical trial has demonstrated that combining the antibody-drug conjugate Trodelvy® with the ...

Nimbus Therapeutics announced the launch of a first-in-human clinical trial for NDI-219216, its investigational Werner ...

Boehringer Ingelheim has announced a collaboration with Tessellate Bio, to develop a new class of targeted therapies for ...

Biosciences announced the first patient has been dosed in its Phase 2 trial of MB-105, a first-in-class CD5-targeted CAR-T ...

In the phase 3 HARMONi-6 trial, ivonescimab, Akeso’s PD-1/VEGF bispecific antibody, combined with chemotherapy, demonstrated ...